IDEAS home Printed from https://ideas.repec.org/a/spr/drugsa/v41y2018i12d10.1007_s40264-018-0708-5.html
   My bibliography  Save this article

Enhancing Pharmacovigilance Capabilities in the EU Regulatory Network: The SCOPE Joint Action

Author

Listed:
  • Anna Radecka

    (Medicines and Healthcare products Regulatory Agency (MHRA))

  • Louise Loughlin

    (Medicines and Healthcare products Regulatory Agency (MHRA))

  • Mick Foy

    (Medicines and Healthcare products Regulatory Agency (MHRA))

  • Margarida Viana de Ferraz Guimaraes

    (INFARMED-National Authority of Medicines and Health Products)

  • Viola Macolic Sarinic

    (World Health Organization (WHO))

  • Marina Dimov Giusti

    (Agency for Medicinal Products and Medical Devices of Croatia (HALMED))

  • Marina Lesicar

    (Agency for Medicinal Products and Medical Devices of Croatia (HALMED))

  • Sabine Straus

    (Medicines Evaluation Board (MEB))

  • Dolores Montero

    (Agencia Española de Medicamentos y Productos Sanitarios (AEMPS))

  • Julia Pallos

    (National Institute of Pharmacy and Nutrition (OGYÉI))

  • Jelena Ivanovic

    (Italian Medicines Agency (AIFA))

  • June Raine

    (Medicines and Healthcare products Regulatory Agency (MHRA))

Abstract

In November 2013, a team of European regulators initiated the Strengthening Collaboration for Operating Pharmacovigilance in Europe (SCOPE) Joint Action. Funded by the Health Programme of the European Union, and with contributions from the involved Member States, SCOPE gathered information and expertise on how regulators in Member States run their national pharmacovigilance systems to meet the requirements of the pharmacovigilance legislation that came into effect in June 2012. The SCOPE project evaluated then-current practices and developed tools to further improve the skills and capability in the pharmacovigilance network. The project was divided into eight separate work streams, five of which concentrated on pharmacovigilance topics—collecting information on suspected adverse drug reactions, identifying and managing safety issues (signals), communicating risk and assessing risk minimisation measures, supported by effective quality management systems. The other three work streams focused on the functional aspects—coordination, communication and evaluation of the project. Through the project, SCOPE delivered guidance, training in key aspects of pharmacovigilance, and tools and templates to support best practice. The deliverables provide practical guidance that those working in the European national competent authorities can take to strengthen their national systems. The SCOPE outputs can be useful for other stakeholders involved in pharmacovigilance activities, including the pharmaceutical industry, healthcare professionals, patient and consumer organisations, and academia.

Suggested Citation

  • Anna Radecka & Louise Loughlin & Mick Foy & Margarida Viana de Ferraz Guimaraes & Viola Macolic Sarinic & Marina Dimov Giusti & Marina Lesicar & Sabine Straus & Dolores Montero & Julia Pallos & Jelena, 2018. "Enhancing Pharmacovigilance Capabilities in the EU Regulatory Network: The SCOPE Joint Action," Drug Safety, Springer, vol. 41(12), pages 1285-1302, December.
    • Handle: RePEc:spr:drugsa:v:41:y:2018:i:12:d:10.1007_s40264-018-0708-5
    DOI: 10.1007/s40264-018-0708-5
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40264-018-0708-5
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40264-018-0708-5?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Sieta T. Vries & Maartje J. M. Sar & Amelia Cupelli & Ilaria Baldelli & Anna Marie Coleman & Dolores Montero & Ivana Šipić & Adriana Andrić & Annika Wennberg & Jane Ahlqvist-Rastad & Petra Denig & Pet, 2017. "Communication on Safety of Medicines in Europe: Current Practices and General Practitioners’ Awareness and Preferences," Drug Safety, Springer, vol. 40(8), pages 729-742, August.
    2. Sieta T. de Vries & Maartje J. M. van der Sar & Anna Marie Coleman & Yvette Escudero & Alfonso Rodríguez Pascual & Miguel-Ángel Maciá Martínez & Amelia Cupelli & Ilaria Baldelli & Ivana Šipić & Adrian, 2018. "Safety Communication Tools and Healthcare Professionals’ Awareness of Specific Drug Safety Issues in Europe: A Survey Study," Drug Safety, Springer, vol. 41(7), pages 713-724, July.
    3. Aniello Santoro & Georgy Genov & Almath Spooner & June Raine & Peter Arlett, 2017. "Promoting and Protecting Public Health: How the European Union Pharmacovigilance System Works," Drug Safety, Springer, vol. 40(10), pages 855-869, October.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Esther Vries & Elisabeth Bakker & Taco B. M. Monster & Petra Denig & Peter G. M. Mol, 2022. "Factors Influencing Preferences and Responses Towards Drug Safety Communications: A Conjoint Experiment Among Hospital-Based Healthcare Professionals in the Netherlands," Drug Safety, Springer, vol. 45(11), pages 1369-1380, November.
    2. Esther Vries & Elisabeth Bakker & Remy D. C. Francisca & Stijn Croonen & Petra Denig & Peter G. M. Mol, 2022. "Handling of New Drug Safety Information in the Dutch Hospital Setting: A Mixed Methods Approach," Drug Safety, Springer, vol. 45(4), pages 369-378, April.
    3. Katherine Chinchilla & Cristiano Matos & Victoria Hall & Florence Hunsel, 2021. "Patient Organizations’ Barriers in Pharmacovigilance and Strategies to Stimulate Their Participation," Drug Safety, Springer, vol. 44(2), pages 181-191, February.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:41:y:2018:i:12:d:10.1007_s40264-018-0708-5. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.